There are currently 16 active clinical trials seeking participants for Primary Sclerosing Cholangitis research studies. The states with the highest number of trials for Primary Sclerosing Cholangitis participants are California, Virginia, Texas and Florida.
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Recruiting
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC). Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 months post-treatment following treatment with hymecromone plus standard of care compared with standard of care. To evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely:... Read More
Gender:
ALL
Ages:
Between 14 years and 75 years
Trial Updated:
11/24/2024
Locations: Stanford Clinic, Redwood City, California +1 locations
Conditions: Primary Sclerosing Cholangitis
A Study of SIPLIZUMAB in AILD and LT Patients
Recruiting
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York
Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
Recruiting
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.
Gender:
ALL
Ages:
Between 15 years and 80 years
Trial Updated:
04/19/2024
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Recruiting
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Gender:
ALL
Ages:
Between 2 weeks and 40 years
Trial Updated:
11/10/2016
Locations: Sacramento Pediatric Gastroenterology, Sacramento, California
Conditions: Primary Sclerosing Cholangitis, Biliary Atresia